News | October 29, 2019

Deciphera Pharmaceuticals Presents Updated Data from Ripretinib and DCC-3014 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics – Median Progression Free Survival (mPFS) of 46 Weeks for the Second-Line...

News | August 14, 2019

Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock WALTHAM, Mass.–(BUSINESS WIRE)–Aug. 14, 2019– Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key...